Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency
28 juin 2021 16h12 HE
|
Chiasma
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology...
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly
27 mai 2021 16h05 HE
|
Chiasma
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial...
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences
20 mai 2021 08h00 HE
|
Chiasma
-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting -- NEEDHAM, Mass., May 20,...
Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt
05 mai 2021 07h05 HE
|
Chiasma
Announced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage...
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
05 mai 2021 07h00 HE
|
Chiasma
- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline - Lead...
Chiasma to Report First Quarter Financial Results on May 6, 2021
29 avr. 2021 08h00 HE
|
Chiasma
NEEDHAM, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio...
Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021
22 mars 2021 16h01 HE
|
Chiasma
--93% of all patients who enrolled as a responder to MYCAPSSA® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was...
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021
20 mars 2021 11h00 HE
|
Chiasma
--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly...
Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021
10 mars 2021 08h00 HE
|
Chiasma
-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage...
Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
04 mars 2021 16h01 HE
|
Chiasma
Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4,...